<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2025-03-18</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0000882361</issuerCik>
        <issuerName>Aptose Biosciences Inc.</issuerName>
        <issuerTradingSymbol>APTO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001904921</rptOwnerCik>
            <rptOwnerName>Hanmi Pharmaceutical Co., Ltd.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>14 WIRYESEONG-DAERO, SONGPA-GU</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>SEOUL</rptOwnerCity>
            <rptOwnerState>M5</rptOwnerState>
            <rptOwnerZipCode>05545</rptOwnerZipCode>
            <rptOwnerStateDescription>KOREA, REPUBLIC OF</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isTenPercentOwner>true</isTenPercentOwner>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Shares</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>508710</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Warrants to Purchase Common Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>51.3</value>
                <footnoteId id="F2"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2024-01-31</value>
            </exerciseDate>
            <expirationDate>
                <value>2029-01-31</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>77972</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.</footnote>
        <footnote id="F2">Represents the exercise price per Common Share of the Issuer issuable upon the exercise of the Warrants, as adjusted following the Issuer's 30-to-1 reverse stock split.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>HANMI PHARMACEUTICAL CO., LTD.; By: /s/ Haegon Shin, Managing Director, Global Business Division</signatureName>
        <signatureDate>2025-03-20</signatureDate>
    </ownerSignature>
</ownershipDocument>
